ClinicalTrials.gg
CompletedNCT00679432Updated Dec 10, 2019Results posted

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

A Phase 3 interventional study of Blood sampling, endoscopy and budesonide-MMX® 6 mg in Ulcerative Colitis, sponsored by Bausch Health Americas, Inc.. Completed at 105 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Bausch Health Companies Inc..

Enrollment
2nd of 18
510 · median 273
Started
2008
with 2 others
Phase 3
14 of 18
none open now
Registered
5th of 18
by date

Among the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., this one is the 2nd largest by enrollment, is one of 3 that started in 2008, is one of 14 in phase 3, and was the 5th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

The purpose of this study is to compare Budesonide MMX™ 6 mg and Budesonide MMX™ 9 mg tablets to placebo and to Asacol 6x 400 mg tablets over an 8-week treatment period to determine if Budesonide MMX™ is effective in the treatment of ulcerative colitis.

Read the detailed description

Each patient will receive one of the following regimens in the morning after breakfast:

  1. one budesonide-MMX™ 6 mg tablet plus two placebo Asacol® over encapsulated tablets, or
  2. one budesonide-MMX™ 9 mg tablet plus two placebo Asacol® over encapsulated tablets, or
  3. two placebo Asacol® over encapsulated tablets plus one placebo budesonide tablet, or
  4. two Asacol® 400 mg over encapsulated tablets plus one placebo budesonide tablet, daily for 8 weeks.

Each patient will also receive on each day after the midday meal and after the evening meal either:

  • two Asacol® 400 mg over-encapsulated tablets (Group 4), or
  • the equivalent placebo Asacol® over-encapsulated tablets, (Groups 1, 2 and 3)

Hence, each patient is to take seven tablets per day of active or placebo study medication as per the randomization schedule. Placebo tablets of budesonide-MMX™ and placebo over-encapsulated tablets of Asacol® will be used to maintain the study blind using a double-dummy technique.

During the study, five visits to the clinical center are scheduled: one at Screening and three in the double-blind treatment period (Day 1, Day 14, Day 28 and Day 56). A safety follow up visit will take place about 2 weeks after the final study visit. If a patient is withdrawn from the study before Day 56, they will be asked to attend the study center as soon as possible thereafter so that the Final visit assessments can be conducted.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative colitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fulfilling the following criteria at the screening visit are eligible for participation in the study:

    • Male and female patients, 18-75 years old, suffering from ulcerative colitis for at least 6 months.
    • Diagnosis of ulcerative colitis in active phase, of mild or moderate entity with Ulcerative Colitis Disease Activity Index (UCDAI) ≥ 4 and ≤ 10 according to Sutherland.
    • All females of must have a negative serum pregnancy test immediately prior to enrollment. In addition, all females of child-bearing potential must agree to be completely abstinent or be using an accepted form of throughout the entire study period. Accepted forms of contraception are defined as those with a failure rate \<1% when properly applied and include: combination oral pill, some intra-uterine devices, and a sterilised partner in a stable relationship. Female subjects must also not be actively breast-feeding through the entire study period.
    • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects.
    • Ability to co-operate with the investigator and to comply with the requirements of the entire study.
    • Must be able to understand and voluntarily sign written prior to inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria at screening visit are to be excluded from study participation:

    • Patients with limited distal proctitis (from anal verge up to 15 cm above the pectineal line).
    • Patients with severe ulcerative colitis (UCDAI >10).
    • Patients with infectious colitis.
    • Evidence or history of toxic megacolon.
    • Severe anemia, leucopenia or granulocytopenia.
    • Use of oral or rectal in the last 4 weeks.
    • Use of immuno-suppressive agents in the last 8 weeks before the study.
    • Use of anti tumor necrosis factor alpha (anti-TNFα) agents in the last 3 months.
    • Concomitant use of any rectal preparation.
    • Concomitant use of antibiotics.
    • Concurrent use of cytochrome P450 3A4 () inducers or CYP3A4 inhibitors.
    • Patients with intolerance to salicylates.
    • Patients with verified, presumed or expected pregnancy or ongoing lactation.
    • Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiency, and/or severe impairment of the bio-humoral parameters (i.e. 2 x for [ALT], aspartate aminotransferase [AST], gamma glutamyl transpeptidase [GGT] or creatinine).
    • Patient with severe diseases in other organs and systems.
    • Patients with local or systemic complications or other pathological states requiring a therapy with corticosteroids and/or immuno-suppressive agents.
    • Patients diagnosed with type 1 diabetes.
    • Patients diagnosed with, or with a family history of, glaucoma.
    • All patients with known , or with (HIV), according to the local privacy policy.
    • Participation in experimental therapeutic studies in the last 3 months. (Note: patients who participated in observational only studies are not excluded).
    • Any other medical condition that in the principal investigator's opinion would make the administration of the study drug or study procedures hazardous to the subject or obscure the interpretation of adverse events (AEs).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (actual)

Study arms

  • Experimental
    1: budesonide-MMX® 6 mg

    One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.

    Procedure: Blood sampling, endoscopy · Drug: budesonide-MMX® 6 mg

  • Experimental
    2: budesonide-MMX® 9 mg

    One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.

    Procedure: Blood sampling, endoscopy · Drug: budesonide-MMX® 9 mg

  • Placebo comparator
    3: Placebo

    Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.

    Procedure: Blood sampling, endoscopy · Drug: Placebo

  • Active comparator
    4: Asacol® 400 mg

    Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.

    Procedure: Blood sampling, endoscopy · Drug: Asacol® 400 mg

Interventions

  • ProcedureBlood sampling, endoscopy

    Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

  • Drugbudesonide-MMX® 6 mg

    6 mg/day, 6 mg tablets

  • Drugbudesonide-MMX® 9 mg

    9 mg/day, 9 mg tablets

  • DrugPlacebo

    Placebo

  • DrugMesalamineStudies of MesalamineMesalamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2400 mg/day, 400 mg tablets

06

What researchers measure

Primary outcomes

  1. Clinical and Endoscopic Remission.

    Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.

    Time frame: 8 weeks

Secondary outcomes

  1. Clinical Improvement.

    Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.

    Time frame: 8 weeks

  2. Endoscopic Improvement

    Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8. As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.

    Time frame: 8 weeks

07

Results

Posted Aug 1, 2014

Participant flow

Recruited from August 2008 until May 2010.

Participant flow — Overall Study
Milestone1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mg
Started126127129127
Completed89897695
Not completed37385332
Withdrew: Adverse event56107
Withdrew: Protocol violation1121
Withdrew: Withdrawal by subject811109
Withdrew: Lost to follow-up1542
Withdrew: Physician decision3222
Withdrew: Sponsor decision1000
Withdrew: Lack of efficacy139148
Withdrew: Infectious colitis, normal histology5483
Withdrew: Randomization error, return to prior rx0030

Outcome measures

PrimaryClinical and Endoscopic Remission.

Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Clinical and Endoscopic Remission.
percentage of patients1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mg
Clinical and Endoscopic Remission.13.2 (7.2 to 19.3)17.9 (11.1 to 24.7)7.4 (2.8 to 12.1)12.1 (6.4 to 17.8)
Statistical analysis
  • 1: Budesonide-MMX® 6 mg vs 3: Placebo · Chi-squared · p = 0.1393 · Difference in proportions: 5.8 · 95% CI -1.8 to 13.4The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).
  • 2: Budesonide-MMX® 9 mg vs 3: Placebo · Chi-squared · p = 0.0143 · Difference in proportions: 10.4 · 95% CI 2.2 to 18.7See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).
  • 3: Placebo vs 4: Asacol® 400 mg · Chi-squared · p = 0.2200 · Difference in proportions: 4.7 · 95% CI -2.7 to 12.1See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).
SecondaryClinical Improvement.

Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Clinical Improvement.
percentage of patients1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mg
Clinical Improvement.30.6 (22.4 to 38.8)33.3 (25.0 to 41.7)24.8 (17.1 to 32.5)33.9 (25.5 to 42.2)
Statistical analysis
  • 1: Budesonide-MMX® 6 mg vs 3: Placebo · Chi-squared · p = 0.3146 · Difference in proportions: 5.8 · 95% CI -5.5 to 17.0The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).
  • 2: Budesonide-MMX® 9 mg vs 3: Placebo · Chi-squared · p = 0.1420 · Difference in proportions: 8.5 · 95% CI -2.8 to 19.9See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).
  • 3: Placebo vs 4: Asacol® 400 mg · Chi-squared · p = 0.1189 · Difference in proportions: 9.1 · 95% CI -2.3 to 20.4See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).
SecondaryEndoscopic Improvement

Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8. As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Endoscopic Improvement
percentage of patients1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mg
Endoscopic Improvement35.5 (27 to 44.1)41.5 (32.8 to 50.2)33.1 (24.7 to 41.4)33.1 (24.8 to 41.3)
Statistical analysis
  • 3: Placebo vs 4: Asacol® 400 mg · Chi-squared · p = 0.9991 · Difference in proportions: 0.0 · 95% CI -11.8 to 11.8The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).

Adverse events

Collected over 56 day ± 2 day (study duration) + 30 day safety followup period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1: Budesonide-MMX® 6 mg—2/126 (1.6%)35/126 (27.8%)
2: Budesonide-MMX® 9 mg—3/127 (2.4%)36/127 (28.3%)
3: Placebo—3/129 (2.3%)34/129 (26.4%)
4: Asacol® 400 mg—4/127 (3.1%)31/127 (24.4%)
Most frequent serious events
Most frequent serious events
Event1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mg
Colitis ulcerativeGastrointestinal disorders1/1263/1271/1291/127
Cerebrovascular accidentNervous system disorders1/1260/1270/1290/127
DiarrhoeaGastrointestinal disorders0/1261/1270/1290/127
Large intestine perforationGastrointestinal disorders0/1261/1270/1290/127
PancreatitisGastrointestinal disorders0/1260/1270/1291/127
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1260/1270/1291/127
AsthmaRespiratory, thoracic and mediastinal disorders0/1261/1270/1290/127
Pyoderma gangrenosumSkin and subcutaneous tissue disorders0/1260/1270/1291/127
Pelvic abscessInfections and infestations0/1260/1271/1290/127
Deep vein thrombosisVascular disorders0/1260/1271/1290/127
Most frequent other events
Showing 10 of 35
Most frequent other events
Event1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mg
Colitis ulcerativeGastrointestinal disorders15/12612/12720/12912/127
HeadacheNervous system disorders17/1268/12719/12912/127
Abdominal painGastrointestinal disorders2/1266/1278/12910/127
NauseaGastrointestinal disorders5/1265/1278/12910/127
PyrexiaGeneral disorders5/1263/1279/1293/127
InsomniaPsychiatric disorders6/1265/1279/1293/127
DiarrhoeaGastrointestinal disorders5/1261/1277/1298/127
FlatulenceGastrointestinal disorders1/1261/1272/1297/127
Back painMusculoskeletal and connective tissue disorders4/1265/1277/1292/127
DizzinessNervous system disorders6/1260/1271/1294/127

Baseline characteristics

Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3\[infectious colitis\] - 17\[normal histology at baseline\] = 489).

Age, Categorical
Age, Categorical(Participants)1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mgTotal
<=18 years00000
Between 18 and 65 years117122115118472
>=65 years416617
Age, Continuous
Age, Continuous(years)1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mgTotal
Mean43.2 ± 1341.7 ± 12.241.7 ± 13.644 ± 12.442.7 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mgTotal
Female62465355216
Male59776869273
Region of Enrollment
Region of Enrollment(participants)1: Budesonide-MMX® 6 mg2: Budesonide-MMX® 9 mg3: Placebo4: Asacol® 400 mgTotal
United States75767776304
Canada575623
India41403942162
08

Study locations

105 sites
  • Santarus Clinical Investigational Site 5051
    Huntsville, Alabama 35801, United States
  • Santarus Clinical Investigational Site 5102
    Mobile, Alabama 36606, United States
  • Santarus Clinical Investigational Site 5014
    Sylacauga, Alabama 35150, United States
  • Santarus Clinical Investigational Site 5088
    Tucson, Arizona 85712, United States
  • Santarus Clinical Investigational Site 5044
    Anaheim, California 92801, United States
  • Santarus Clinical Investigational Site 5099
    Encinitas, California 92024, United States
  • Santarus Clinical Investigational Site 5075
    Fremont, California 94536, United States
  • Santarus Clinical Investigational Site 5087
    Lakewood, California 90712, United States
  • Santarus Clinical Investigational Site 5033
    Los Angeles, California 90045, United States
  • Santarus Clinical Investigational Site 5070
    Palm Springs, California 92262, United States
  • Santarus Clinical Investigational Site 5067
    San Diego, California 92101, United States
  • Santarus Clinical Investigational Site 5028
    San Francisco, California 94117, United States
  • Santarus Clinical Investigational Site 5089
    Boynton Beach, Florida 33426, United States
  • Santarus Clinical Investigational Site 5041
    Hollywood, Florida 33021, United States
  • Santarus Clinical Investigational Site 5055
    New Smyrna Beach, Florida 32168, United States
  • Santarus Clinical Investigational Site 5074
    Port Orange, Florida 32127, United States
  • Santarus Clinical Investigational Site 5032
    Tampa, Florida 33607, United States
  • Santarus Clinical Investigational Site 5009
    Tampa, Florida 33613, United States
  • Santarus Clinical Investigational Site 5110
    West Palm Beach, Florida 33409, United States
  • Santarus Clinical Investigational Site 5047
    Winter Park, Florida 32789, United States
  • Santarus Clinical Investigational Site 5003
    Zephyrhills, Florida 33542, United States
  • Santarus Clinical Investigational Site 5016
    Atlanta, Georgia 30312, United States
  • Santarus Clinical Investigational Site 5056
    Columbus, Georgia 31904, United States
  • Santarus Clinical Investigational Site 5103
    Savannah, Georgia 31406, United States
  • Santarus Clinical Investigational Site 5085
    Addison, Illinois 60101, United States
  • Santarus Clinical Investigational Site 5068
    Evanston, Illinois 60201, United States
  • Santarus Clinical Investigational Site 5086
    Bloomington, Indiana 47403, United States
  • Santarus Clinical Investigational Site 5053
    Clive, Iowa 50325, United States
  • Santarus Clinical Investigational Site 5008
    Metairie, Louisiana 70006, United States
  • Santarus Clinical Investigational Site 5090
    Annapolis, Maryland 21401, United States
  • Santarus Clinical Investigational Site 5025
    Baltimore, Maryland 21229, United States
  • Santarus Clinical Investigational Site 5092
    Hollywood, Maryland 20636, United States
  • Santarus Clinical Investigational Site 5077
    Prince Frederick, Maryland 20678, United States
  • Santarus Clinical Investigational Site 5046
    Boston, Massachusetts 02114, United States
  • Santarus Clinical Investigational Site 5115
    Brockton, Massachusetts 02301, United States
  • Santarus Clinical Investigational Site 5010
    Chesterfield, Michigan 48047, United States
  • Santarus Clinical Investigational Site 5006
    Troy, Michigan 48098, United States
  • Santarus Clinical Investigational Site 5004
    Wyoming, Michigan 49519, United States
  • Santarus Clinical Investigational Site 5105
    Saint Louis, Missouri 63128, United States
  • Santarus Clinical Investigational Site 5094
    Egg Harbor Township, New Jersey 08234, United States
  • Santarus Clinical Investigational Site 5005
    Marlton, New Jersey 08053, United States
  • Santarus Clinical Investigational Site 5024
    Vineland, New Jersey 08360, United States
  • Santarus Clinical Investigational Site 5011
    Great Neck, New York 11021, United States
  • Santarus Clinical Investigational Site 5101
    New York, New York 10016, United States
  • Santarus Clinical Investigational Site 5020
    Pittsford, New York 14534, United States
  • Santarus Clinical Investigational Site 5096
    Fayetteville, North Carolina 28304, United States
  • Santarus Clinical Investigational Site 5058
    Huntersville, North Carolina 28078, United States
  • Santarus Clinical Investigational Site 5091
    New Bern, North Carolina 28562, United States
  • Santarus Clinical Investigational Site 5124
    Wilmington, North Carolina 28403, United States
  • Santarus Clinical Investigational Site 5118
    Canton, Ohio 44701, United States
  • Santarus Clinical Investigational Site 5045
    Cincinnati, Ohio 45218, United States
  • Santarus Clinical Investigational Site 5078
    Dayton, Ohio 45440, United States
  • Santarus Clinical Investigational Site 5120
    Mentor, Ohio 44060, United States
  • Santarus Clinical Investigational Site 5066
    Duncansville, Pennsylvania 16635, United States
  • Santarus Clinical Investigational Site 5065
    Pottstown, Pennsylvania 19464, United States
  • Santarus Clinical Investigational Site 5035
    Sayre, Pennsylvania 18840, United States
  • Santarus Clinical Investigational Site 5107
    Sioux Falls, South Dakota 57105, United States
  • Santarus Clinical Investigational Site 5130
    Jackson, Tennessee 38305, United States
  • Santarus Clinical Investigational Site 5095
    Kingsport, Tennessee 37660, United States
  • Santarus Clinical Investigational Site 5021
    Austin, Texas 78745, United States
  • Santarus Clinical Investigational Site 5076
    Houston, Texas 77034, United States
  • Santarus Clinical Investigational Site 5108
    Houston, Texas 77079, United States
  • Santarus Clinical Investigational Site 5019
    Houston, Texas 77090, United States
  • Santarus Clinical Investigational Site 5036
    Houston, Texas 77090, United States
  • Santarus Clinical Investigational Site 5063
    Irving, Texas 75061, United States
  • Santarus Clinical Investigational Site 5072
    Kingwood, Texas 77339, United States
  • Santarus Clinical Investigational Site 5054
    La Porte, Texas 77571, United States
  • Santarus Clinical Investigational Site 5030
    Lewisville, Texas 75057, United States
  • Santarus Clinical Investigational Site 5093
    Plano, Texas 75075, United States
  • Santarus Clinical Investigational Site 5049
    San Antonio, Texas 78229, United States
  • Santarus Clinical Investigational Site 5100
    San Antonio, Texas 78229, United States
  • Santarus Clinical Investigational Site 5079
    San Antonio, Texas 78258, United States
  • Santarus Clinical Investigational Site 5098
    Tomball, Texas 77375, United States
  • Santarus Clinical Investigational Site 5015
    Salt Lake City, Utah 84107, United States
  • Santarus Clinical Investigational Site 5097
    Christiansburg, Virginia 24073, United States
  • Santarus Clinical Investigational Site 5119
    Norfolk, Virginia 23502, United States
  • Santarus Clinical Investigational Site 6005
    Abbotsford, British Columbia V2S 3N5, Canada
  • Santarus Clinical Investigational Site 6000
    Vancouver, British Columbia V5Z 1H2, Canada
  • Santarus Clinical Investigational Site 6014
    Vancouver, British Columbia V6Z 2K5, Canada
  • Santarus Clinical Investigational Site 6008
    Victoria, British Columbia V8R 1J8, Canada
  • Santarus Clinical Investigational Site 6004
    Richmond Hill, Ontario L4B 3P8, Canada
  • Santarus Clinical Investigational Site 6017
    Toronto, Ontario M4N 3N5, Canada
  • Santarus Clinical Investigational Site 6001
    Montreal, Quebec H1T 2M4, Canada
  • Santarus Clinical Investigational Site 6016
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Santarus Clinical Investigational Site 6002
    Quebec, G1R 2J6, Canada
  • Santarus Clinical Investigational Site 6006
    Toronto, M3N 2V7, Canada
  • Santarus Clinical Investigational Site 9001
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9009
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9012
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9016
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9006
    Assam, India
  • Santarus Clinical Investigational Site 9007
    Gujarat, India
  • Santarus Clinical Investigational Site 9004
    Karnataka, India
  • Santarus Clinical Investigational Site 9015
    Karnataka, India
  • Santarus Clinical Investigational Site 9003
    Kerala, India
  • Santarus Clinical Investigational Site 9002
    Maharashtra, India
  • Santarus Clinical Investigational Site 9008
    Maharashtra, India
  • Santarus Clinical Investigational Site 9010
    Maharashtra, India
  • Santarus Clinical Investigational Site 9011
    Maharashtra, India
  • Santarus Clinical Investigational Site 9013
    Maharashtra, India

Showing the first 100 of 105 sites across 4 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov;143(5):1218-1226.e2. doi: 10.1053/j.gastro.2012.08.003. Epub 2012 Aug 11. PubMed 22892337 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 years 3 months after primary completion. A results delay was requested in Dec 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2008
First posted
May 16, 2008
Start
Jun 2008
Primary completionActual
May 2010
CompletionActual
Jun 2010
Results delay requested
Dec 1, 2011
Results first posted
Aug 1, 2014
Last update
Dec 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00679432
Responsible party
Sponsor
First posted
May 16, 2008
Start date
Jun 2008
Primary completion
May 2010
Completion
Jun 2010
Results posted
Aug 1, 2014
Last update
Dec 10, 2019

Study contacts

Bruce Eric Sands
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion